今後のイベント
すべてのイベント
今後のイベント予定はありません
概要分析
売上高と純利益
すべてのパラメータ
株式ニュース
すべてのニュース
30 5月 в 14:45
30 5月 в 14:45
30 5月 в 14:45
30 5月 в 14:45
30 5月 в 14:45
30 5月 в 14:35
30 5月 в 14:15
30 5月 в 14:10
Bolt Biotherapeutics, Inc., a clinical-stage immuno-oncology company, engages in the discovery, development, and commercialization of pharmaceutical products. The company develops BDC-1001, a human epidermal growth factor receptor 2 (HER2) for the treatment of patients with HER2-expressing solid tumors, including HER2-low tumors; and BDC-2034, a carcinoembryonic antigen program for colorectal, non-small cell lung, pancreatic, and breast cancers. It is also developing programmed cell death-ligand 1 program for tumors that are nonresponsive to immune checkpoint blockade; and myeloid modulators. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood city, California.
住所:
900 Chesapeake Drive, Redwood City, CA, United States, 94063
会社名:
発行会社ティッカー:
BOLT
ISIN:
US0977021049
国:
アメリカ合衆国
交換:
ACRA
通貨:
$
IPOの日付:
2021-02-05
セクタ:
健康管理
業界:
バイオテクノロジー
サイト:
https://www.boltbio.com
https://www.boltbio.com
